

JUL 16 2007

MORRISON FOERSTER	755 PAGE MILL ROAD	MORRISON & FOERSTER LLP NEW YORK, SAN FRANCISCO, LOS ANGELES, PALO ALTO, SAN DIEGO, WASHINGTON, D.C. DENVER, NORTHERN VIRGINIA, ORANGE COUNTY, SACRAMENTO, WALNUT CREEK, CENTURY CITY TOKYO, LONDON, BEIJING, SHANGHAI, HONG KONG, SINGAPORE, BRUSSELS
	PALO ALTO	
	CALIFORNIA 94304-1018	
	TELEPHONE: 650.813.5600	
	FACSIMILE: 650.494.0792	
	WWW.MOFO.COM	

To:

NAME:	FACSIMILE:	TELEPHONE:
Commissioner of Patents U.S. Patent & Trademark Office	(571) 273-8300	(571) 272-4000

FROM: Robert K. Cerpa

DATE: July 16, 2007

Number of pages with cover page:	4	Originals Will Not Follow
-------------------------------------	---	---------------------------

Preparer of this slip has confirmed that facsimile number given is correct: 12056/eag4

Comments:

Attorney Docket No.: 526302001220
 Group Art Unit: 1626
 Examiner: D. Lambkin
 Application No.: 10/667,280
 Filing Date: September 17, 2003
 Patent Number: 7,078,541
 Issue Date: July 18, 2006
 Inventor(s) Sekhar BODDUPALLI et al.
 Title: BENZOFURAN DERIVATIVES

Papers Enclosed:

- (1) Transmittal Form (1 page)
- (2) Statement Under 37 CFR 3.73(b) (1 page)
- (3) Power of Attorney (1 page)

To ensure compliance with requirements imposed by the United States Internal Revenue Service, Morrison & Foerster LLP informs you that, if any advice concerning one or more U.S. Federal tax issues is contained in this facsimile (including any attachments), such advice is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

CAUTION - CONFIDENTIAL

This facsimile contains confidential information that may also be privileged. Unless you are the addressee (or authorized to receive for the addressee); you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
 ELSA GUEZIEC AT 650 813-5862 AS SOON AS POSSIBLE.

PA-1179624

JUL 16 2007

PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/667,280
		Patent Number	7,078,541
		Filing Date	September 17, 2003
		Issue Date	July 18, 2006
		First Named Inventor	Sekhar BODDUPALLI
		Art Unit	1626
		Examiner Name	D. Lambkin
Total Number of Pages in This Submission	3	Attorney Docket Number	526302001220

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address (1 page) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (1 page) Fax cover sheet
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Robert K. Cerpa		
Date	July 16, 2007	Reg. No.	39933

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile (Fax No. 571-273-8300) to the USPTO Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: July 16, 2007	Signature: <u>E. Guezlec</u> Elsa Guezlec

pa-1141585

JUL 16 2007

PTO/SB/99 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Sekhar BODDUPALLI et al.Application No./Patent No.: 10/667,280/7,078,541 Filed/Issue Date: September 17, 2003/July 18, 2006Entitled: BENZOFURAN DERIVATIVESEdison Pharmaceuticals, Inc., a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Bing WANG and Jian CHEN To: Galileo Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 014244, Frame 0503, or for which a copy thereof is attached.
2. From: Sekhar BODDUPALLI; Gail WALKINSHAW; Bing WANG To: Galileo Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 014603, Frame 0371, or for which a copy thereof is attached.
3. From: Galileo Pharmaceuticals, Inc. To: Edison Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 019287, Frame 0696, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Guy Miller, M.D., Ph.D.
Signature
Printed or Typed Name
CEO, Edison Pharmaceuticals, Inc.
Title

June 29, 2007
Date
Telephone Number
(408) 960-2901

Attorney Docket: 526302001220

PA-1141605

JUL 16 2007

PTO/SB/82 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/667,280
	Patent Number	7,078,541
	Filing Date	September 17, 2003
	Issue Date	July 18, 2006
	First Named Inventor	Sekhar BODDUPALLI
	Art Unit	1626
Examiner Name	D. Lambkin	
Attorney Docket Number	526302001220	

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 25226☒ Please change the correspondence address for the above-identified application to:☒ The address associated with
Customer Number:

25226

OR

☐ Firm or
Individual Name

Address

City

Country

State

Zip

Telephone

Email

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature

Name

Guy Miller M.D., Ph.D., CEO, Edison Pharmaceuticals, Inc.

Date

June 29, 2007

Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒

*Total of

1

forms are submitted.

pa-1141231